Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ibrutinib by AbbVie for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
Ibrutinib is under clinical development by AbbVie and currently in Phase III for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid...
Ibrutinib by AbbVie for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Ibrutinib is under clinical development by AbbVie and currently in Phase III for Splenic Marginal Zone B-Cell Lymphoma. According to...
Ibrutinib by AbbVie for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Ibrutinib is under clinical development by AbbVie and currently in Phase III for Nodal Marginal Zone B-Cell Lymphoma. According to...
Ibrutinib by AbbVie for Follicular Lymphoma: Likelihood of Approval
Ibrutinib is under clinical development by AbbVie and currently in Phase III for Follicular Lymphoma. According to GlobalData, Phase III...
Ibrutinib by AbbVie for Myelodysplastic Syndrome: Likelihood of Approval
Ibrutinib is under clinical development by AbbVie and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II...
Ibrutinib by AbbVie for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Ibrutinib is under clinical development by AbbVie and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)....
Ibrutinib by AbbVie for Primary CNS Lymphoma: Likelihood of Approval
Ibrutinib is under clinical development by AbbVie and currently in Phase II for Primary CNS Lymphoma. According to GlobalData, Phase...
Ibrutinib by AbbVie for Renal Cell Carcinoma: Likelihood of Approval
Ibrutinib is under clinical development by AbbVie and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase...